Impact of a Personalized Medication Plan on Duration of Treatment With Potent Opioids in Acute Non-cancer Musculoskeletal Pain.

Recruiting now · Not applicable

Conditions studied: Acute Pathology of the Locomotor System

In brief

The aim of this study is to evaluate whether patients who benefit from a personalized pharmaceutical plan (PPP) during their hospitalization, allowing them to be informed and sensitized, are treated for a shorter period of time with strong opioids with a reduced risk of dependence compared to a management according to the usual modalities in the rheumatology services concerned.

Key facts

Study ID: NCT05905146
Run by: University Hospital, Rouen
People needed: 200
Starts: 2024-01-18
Expected to finish: 2028-07-18
Last updated by the study team: 2026-02-06

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

Patient hospitalized in the rheumatology department
Patient with acute pain in the context of a non-cancerous, non-traumatic, high-energy musculoskeletal pathology
Patient for whom a prescription of strong opioid derivatives is initiated in rheumatology or patient for whom a prescription of strong opioid derivatives is maintained in rheumatology if the initial prescription has a maximum duration of 30 consecutive days prior to inclusion

You may not qualify if…

Patient with cancer or fibromyalgia already diagnosed at inclusion
Patient with poor French language skills
Taking a strong opioid treatment for more than 30 consecutive days prior to inclusion
Person judged by the prescriber or pharmacist as not autonomous for the management of strong opioid treatment
Patient already included in the study

Where it is running

CHU de Lille — Lille, France (enrolling)
CHU de Nimes — Nîmes, France (enrolling)
CHU de ROUEN — Rouen, France (enrolling)

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.